The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3
A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign